Business briefs, April 30
United Therapeutics earnings grew 120 percent in 1Q
Earnings for Maryland-based United Therapeutics grew 120 percent in the first quarter to $137.5 million.
The company, which has manufacturing and other operations in the Research Triangle Park, saw 18 percent revenue growth to $245.14 million on sales of pulmonary arterial hypertension treatments.
The company now has four treatments for the disease after it started selling an oral tablet version, called Orenitram, in April. The new drug contains the same active ingredient that’s in the company’s injection and inhalation medicines.
The company produces Orenitram in the RTP. It also plans to use its own facilities to produce the primary supply of its other medications Remodulin and Tyvaso as well.
The company also has launched construction of a new facility in RTP where it plans to do research into the use of transplantable lungs and lung tissues as a cure for pulmonary arterial hypertension.
The company said in a regulatory filing that the extent to which it will develop the facilities “will depend on the progress of our pre-clinical and clinical development in various early-stage programs.”